BCL2 and endometrial cancer: With additional evidence from previous literature reporting enhanced anti-tumor effects of dual inhibition (inhibition of Bcl-2 and FGFR in endometrial cancer; and of Bcl-2 and mTOR in renal cell carcinoma) (Packer et al. 2019; Nayman et al. 2019), we hypothesize that both signaling pathways may be able to implement resistance to BCL2 inhibition in OVCA and may contain reasonable combination targets with BCL2i.